Faithward Advisors LLC Purchases New Holdings in Xeris Biopharma Holdings, Inc. $XERS

Faithward Advisors LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 106,730 shares of the company’s stock, valued at approximately $838,000. Faithward Advisors LLC owned approximately 0.06% of Xeris Biopharma at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in Xeris Biopharma in the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd grew its stake in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Truvestments Capital LLC grew its stake in Xeris Biopharma by 96.1% in the 4th quarter. Truvestments Capital LLC now owns 8,118 shares of the company’s stock worth $64,000 after acquiring an additional 3,979 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on XERS shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.80.

Insider Buying and Selling

In other Xeris Biopharma news, Director Marla Persky sold 15,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total value of $91,450.00. Following the completion of the sale, the director directly owned 126,500 shares in the company, valued at $746,350. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the completion of the sale, the insider owned 1,176,506 shares of the company’s stock, valued at approximately $7,129,626.36. This trade represents a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 127,335 shares of company stock valued at $766,733 over the last quarter. Insiders own 4.35% of the company’s stock.

Xeris Biopharma Price Performance

Shares of XERS opened at $6.90 on Wednesday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 115.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a twelve month low of $4.40 and a twelve month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company has a 50 day moving average of $6.23 and a two-hundred day moving average of $6.57.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.